TrialCancer immunology, immunotherapy : CII2006

A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.

Myrto Trakatelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.